Abstract
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anticancer agent that selectively triggers apoptosis in various cancer cells by interacting with its proapoptotic receptors DR4 and KILLER/DR5. The intensive studies of TRAIL signaling pathways over the past decade have provided clues for understanding the molecular mechanisms of TRAIL-induced apoptosis in carcinogenesis and identified an array of therapeutic responses elicited by TRAIL and its receptor agonists. Preclinical and clinical studies have shown that recombinant TRAIL and the agonistic mono-antibodies targeting TRAIL receptors exhibit potent tumoricidal activities as monotherapies and that the combinatorial therapies of these agents in conjunction with other anticancer modalities such as chemo or radiotherapy amplify the activities of anticancer agents and widen the therapeutic window by overcoming tumor resistance to apoptosis and driving cancer cells to self-destruction. The identification of a number of biomarkers that predict tumor sensitivity of patients to TRAIL-based therapy shed a new light on the personalized therapeutic strategies targeting the TRAIL/TRAIL receptor pathway.
Keywords: Apoptosis, biomarker, cancer therapy, DR4, drug design, KILLER/DR5, TNF receptor superfamily, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL, TRAIL-induced apoptosis, carcinogenesis, chemo or, radiotherapy, Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL), tissue homeostasis, Excessive apoptosis, AIDS, Alzheimer's diseases, Huntington's disease, cardiac ischemia, deficient apoptosis, caspase-dependent pathway, TNF family, anti-TRAIL receptor, TRAIL-sensitive tumors, resistant tumor, homotrimer, DcR1, DcR2, Osteoprotegerin, mDcR1, mDcR2, interferons, TNF, Eu-myc, 5-FU treatment, (FADD), (DED), death inducing signaling complex, Bax, Bak, Bcl-2, nuclear factor-B, mitogen-activated protein kinases, extracellular signal-regulated kinase, JUN N-terminal kinase, (TRADD), c-FLIP, (TRAF2), (RIP), TRAIL apoptotic pathway, XIAP, GALNT14, GALNT3, FUT 6, FUT 3
Current Medicinal Chemistry
Title: TRAIL: A Sword for Killing Tumors
Volume: 17 Issue: 29
Author(s): S. Wang
Affiliation:
Keywords: Apoptosis, biomarker, cancer therapy, DR4, drug design, KILLER/DR5, TNF receptor superfamily, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL, TRAIL-induced apoptosis, carcinogenesis, chemo or, radiotherapy, Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL), tissue homeostasis, Excessive apoptosis, AIDS, Alzheimer's diseases, Huntington's disease, cardiac ischemia, deficient apoptosis, caspase-dependent pathway, TNF family, anti-TRAIL receptor, TRAIL-sensitive tumors, resistant tumor, homotrimer, DcR1, DcR2, Osteoprotegerin, mDcR1, mDcR2, interferons, TNF, Eu-myc, 5-FU treatment, (FADD), (DED), death inducing signaling complex, Bax, Bak, Bcl-2, nuclear factor-B, mitogen-activated protein kinases, extracellular signal-regulated kinase, JUN N-terminal kinase, (TRADD), c-FLIP, (TRAF2), (RIP), TRAIL apoptotic pathway, XIAP, GALNT14, GALNT3, FUT 6, FUT 3
Abstract: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising anticancer agent that selectively triggers apoptosis in various cancer cells by interacting with its proapoptotic receptors DR4 and KILLER/DR5. The intensive studies of TRAIL signaling pathways over the past decade have provided clues for understanding the molecular mechanisms of TRAIL-induced apoptosis in carcinogenesis and identified an array of therapeutic responses elicited by TRAIL and its receptor agonists. Preclinical and clinical studies have shown that recombinant TRAIL and the agonistic mono-antibodies targeting TRAIL receptors exhibit potent tumoricidal activities as monotherapies and that the combinatorial therapies of these agents in conjunction with other anticancer modalities such as chemo or radiotherapy amplify the activities of anticancer agents and widen the therapeutic window by overcoming tumor resistance to apoptosis and driving cancer cells to self-destruction. The identification of a number of biomarkers that predict tumor sensitivity of patients to TRAIL-based therapy shed a new light on the personalized therapeutic strategies targeting the TRAIL/TRAIL receptor pathway.
Export Options
About this article
Cite this article as:
Wang S., TRAIL: A Sword for Killing Tumors, Current Medicinal Chemistry 2010; 17 (29) . https://dx.doi.org/10.2174/092986710793176285
DOI https://dx.doi.org/10.2174/092986710793176285 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of DNA Damage Checkpoint; Patenting and Possible Application for Cancer Medicine
Recent Patents on DNA & Gene Sequences Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting
Reviews on Recent Clinical Trials Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Small Molecule Integrin Antagonists in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Methotrexate-Induced Pneumonitis: Heterogeneity of Bronchoalveolar Lavage and Differences between Cancer and Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Is Effective and Safe a Radiochemotherapy Approach in Elderly Cancer Patients? A Review
Anti-Cancer Agents in Medicinal Chemistry Malignant Hypercalcemia
Current Medicinal Chemistry Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews In Silico Study and Cytotoxicity of the Synthesized Open-chain Analogues of Antimycin A3 Against HEP-2 Laryngeal Cancer Cells
Current Cancer Therapy Reviews Coumarin Derivatives as Anti-inflammatory and Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Synthesis of a Novel Gold(I) Complex and Evaluation of Its Anticancer Properties in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer
Current Drug Targets Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Targeting Chromatin Remodeling for Cancer Therapy
Current Molecular Pharmacology Integrated Single-cell and Bulk RNA Sequencing Analysis Cross Talk between Ferroptosis-related Genes and Prognosis in Oral Cavity Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued)